Refractory immune thrombocytopenia responding to combination therapy of eltrombopag and low-dose rituximab: a case series
-
Published:2024-08
Issue:
Volume:
Page:
-
ISSN:2531-1379
-
Container-title:Hematology, Transfusion and Cell Therapy
-
language:en
-
Short-container-title:Hematology, Transfusion and Cell Therapy
Author:
Chu Tan-HuyORCID,
Huynh Thien-Ngon,
Trinh-Le Quoc-Vu,
Phu Chi-Dung
Reference10 articles.
1. Immune thrombocytopenia;Cooper;N Engl J Med,2019
2. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab;Stasi;Blood,2008
3. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents;Bao;Blood,2010
4. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group;Rodeghiero;Blood,2009
5. Immune thrombocytopenia - current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI;Matzdorff;Oncol Res Treat,2018